Business:
Novel treatments for gastrointestinal diseases and disorders
Drug notes:
Also NDA errosive GERD, heartburn, Clin3 heartburn in non-erosive GERD, different dosing Clin2 heartburn in non-erosive GERD, Clin2 eosinophilic esophagitis
About:
Phathom Pharmaceuticals is dedicated to improving treatments for gastrointestinal (GI) diseases. They focus on developing innovative therapies for acid-related disorders like ulcers and heartburn. One key area of their research is the development of new proton pump inhibitors – a class of drugs that reduce stomach acid production. While there are existing PPIs on the market, Phathom is investigating more effective and potentially longer-lasting options. This could lead to improved patient outcomes and potentially reduce the need for frequent medication use.
Director Patient Marketing Analytics Florham Park, NJ|32 days ago
Corporate and Securities Counsel Florham Park, NJ|49 days ago
Territory Sales Representative Raleigh, NC|67 days ago
Territory Sales Representative Midland, MI|73 days ago
Regional Sales Manager - Philadelphia PA United States|93 days ago
Manager Market Access Operations Florham Park, NJ|100+ days ago
Territory Sales Representative Troy, MI|Not provided